Pfizer and BioNTech are preparing to begin clinical trials of the Covid-19 vaccine version of the Delta variant next month because of concerns that the existing jabs will weaken the protection of the rapidly spreading infectious strains in most parts of the world.
Pfizer said on Thursday that drugmakers are developing an updated version of the existing vaccine, which will be manufactured using the lineage of the Delta variant. Pfizer and BioNTech are discussing with the U.S. drug regulatory agency to finalize their clinical trial plans, and the research is expected to begin in August.
The two companies were the first to develop a vaccine against Delta variants, a move that highlights concerns that this highly infectious strain may be able to evade existing vaccination and new measures are needed to address it.
The Delta variant was first discovered in India in December and has since swept across Europe and the United States, causing a surge in coronavirus cases, especially among the unvaccinated.Delta Air Lines is now Dominant strains According to data from the Centers for Disease Control and Prevention, in the United States, it accounts for more than 90% of new coronary pneumonia cases in the United Kingdom.
“Although we believe the third dose [our vaccine] It has the potential to maintain the highest level of protection against all currently known variants, including Delta. We remain vigilant and are developing an updated version of Pfizer’s Covid-19 vaccine,” Pfizer said.
A study by the Israeli Ministry of Health this week Indicated The BioNTech/Pfizer injection vaccine has an effective rate of 93% in preventing serious diseases and hospitalizations in Delta, but an effective rate of 64% in preventing infection of this variant.
The latest coronavirus news
Follow the UK’s “Financial Times” on-site reporting and analysis of global epidemics and rapidly evolving economic crises Here.
Pfizer reiterated its belief that a third injection is required 6 to 12 months after the second dose of its two injection boluses to improve immunity to the new variant.
The New York-based company pointed out that preliminary data released last month showed that two doses of the vaccine can trigger antibody titers against the Delta variant, but said that the vaccine’s effectiveness will decrease 6 months after vaccination.
Both Moderna and Johnson & Johnson said that early data showed that their injections would produce antibodies against Delta.